Herbal Preparation and Glucose Homeostasis (Herbie)
Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and accounts for a considerable part of health care costs. Herbal supplements are used in many cultures for the prevention and treatment of many different conditions. Due to lack of scientific proof, the application in western cultures are minimal. Animal studies have shown that many constituents of such herbal supplements may have beneficial effects on several important parameters known to be affected in T2D. Still, no scientific proof in humans is available. We therefore aim to investigate the effect of 4-week herbal supplementation on glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with increased fasting glucose levels or a decreased glucose tolerance.
Objective: The primary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on blood glucose levels and glucose tolerance. The secondary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and during an OGTT test.
Study design: This study is a randomized, double-blind, placebo controlled cross-over trial in which two different treatments will be evaluated e.g. an intervention with the herbal mixture and a placebo. Each person will obtain both treatments in random order for four weeks with a wash out period of four weeks in-between. Fasting blood samples will be collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week supplementation.
Furthermore, after 4-week supplement intake we will collect a urine sample and collect an adipose tissue biopsy. The whole trial will last three months.
Study population: 26 overweight males and females 50-75yrs old with an increased fasting glucose or with an impaired glucose tolerance.
Intervention: Two intervention periods of 4-weeks in which participants will take three times a day a supplement of 500mg herbal or placebo.
Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA, adipose tissue an white blood cell gene expression and markers of inflammation .
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects that will participate in the study will invest a total of 16.5 hours. Blood collection by vena punctures/insertion of the venflon and the collection of an adipose tissue biopsy can occasionally cause a local hematoma or bruise and some participants may report pain or discomfort. The herbal supplements contain small amounts St. John's wort, which may affect the function of liver enzymes. We will therefore monitor liver function parameters during the supplementation period. Furthermore, subjects are excluded if they use medication known to be affected by St. John's wort. Participant will donate 284ml of blood, dispersed over 12 weeks.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Gelderland
-
Wageningen, Gelderland, Holland, 6703 HD
- Wageningen University
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males and postmenopausal females For females: menstrual cycle absent for more than 1 year
- age 50-70yrs
- BMI >27 kg/m2
- Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L).
Exclusion Criteria:
- Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg
- Tobacco smoker
- Received inoculations within 2 months of starting the study or planned during the study
- Donated or intend to donate blood from 2 months before the study till months after the study.
- Unstable body weight (weight gain or loss >5kg in the past three months)
- Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C)
- The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's).
- Abuse of drugs/alcohol
- If the participant don't want to sign the informed consent
- If the participant don't want to be informed about unexpected findings during the screening or study
- Participation in another biomedical study
- Additional exclusion criteria for females:
Current use of contraceptives containing hormones Current use of hormone replacement therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: herbal supplements
500mg, 3 per day, 4weeks
|
|
|
Placebo komparator: placebo
500mg, 3 per day, 4 weeks
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
change in glucose tolerance
Tidsramme: baseline and after 4-week supplementation
|
by oral glucose tolerance test (OGTT)
|
baseline and after 4-week supplementation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
change in insulin
Tidsramme: baseline and after 4-week supplementation
|
baseline and after 4-week supplementation
|
|
|
change in TAG
Tidsramme: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in HbA1c
Tidsramme: baseline and after 4 week supplementation
|
glycosylated haemoglobin
|
baseline and after 4 week supplementation
|
|
change in FFA
Tidsramme: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in cholesterol
Tidsramme: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
change in vascular function
Tidsramme: baseline and after 4-week supplementation
|
by pulse wave analysis (PWA)
|
baseline and after 4-week supplementation
|
|
change in ALAT/ASAT
Tidsramme: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
Urinary metabolites
Tidsramme: after 4 week supplementation
|
after 4 week supplementation
|
|
|
adipose tissue gene expression
Tidsramme: after 4 week supplementation
|
by qpcr
|
after 4 week supplementation
|
|
change in markers of inflammation
Tidsramme: baseline and after 4 week of supplementation
|
by PBMC genexpression and plasma cytokines
|
baseline and after 4 week of supplementation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Lydia A Afman, PhD, Wageningen University
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NL44919.081.13
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Betændelse
-
NCT07293624Tilmelding efter invitationSystemisk inflammation | Bariatrisk kirurgi | Bariatrisk ærmegatrektomi | Diætbetændelsesindeks (DII) | Systemiske inflammationsmarkører | Inflammation
-
NCT07219043Rekruttering
-
NCT07324681Ikke rekrutterer endnuAngiogenese | Healing | Inflammation
-
NCT07395921Ikke rekrutterer endnuInflammatorisk | Antioxidantstatus, inflammation | Inflammation biomarkører | Antioxidant evner | Cardiometabolic sundhedsindikatorer
-
NCT07439185Ikke rekrutterer endnuJernoptagelse | Tarm - Mikrobiota | Inflammation
-
NCT07456683AfsluttetSystemisk inflammation | Hydrering | Hvilemetabolisme
-
NCT07326670RekrutteringSystemisk inflammation | Perkutan nefrolitotomi | Anæstesiteknikker
-
NCT07283744RekrutteringPsykosocial funktion | Stress (psykologi) | Inflammation
-
NCT07264751AfsluttetUddannelse | Motionstræning | Hormon | Inflammation biomarkører
-
NCT07274462Aktiv, ikke rekrutterendeMikrovaskulær Inflammation - MVI hos Nyretransplantatmodtagere
Kliniske forsøg med herbal supplement
-
NCT03837210Afsluttet
-
NCT06872827Afsluttet
-
NCT01955044AfsluttetFor tidligt fødte spædbørn med ekstremt lav fødselsvægt | Niveauer af flerumættede fedtsyrer
-
NCT06965491AfsluttetEndurance Cycling Performance | Eksogen ketose | Træthed, mentalt | Træthed; Muskel, hjerte
-
NCT02321631Afsluttet
-
NCT04765852AfsluttetProbiotisk tilskud
-
NCT03751813AfsluttetSvangerskabsdiabetes